CELLINK, the creator of one of the world's first universal bioinks, has completed a directed share issue which will provide CELLINK with proceeds of approximately SEK 377 million.

The purpose of the share issue is to finance CELLINK’s growth agenda.

Carnegie Investment Bank acted as sole bookrunner in connection with the transaction. Baker McKenzie acted as legal advisor to Carnegie Investment Bank as to US law. The Baker McKenzie team mainly consisted of Henric Roth from Stockholm and Roger James, Charles Farnsworth and Andrew J. Brown from London.

Explore Our Newsroom